LONDON (Alliance News) - Hormonal disease-focused drug firm Diurnal Group PLC on Monday said the first patient has been dosed in testosterone replacement therapy trials.
Diurnal said the study will test the pharmokinetics, safety and tolerability of its DITEST drug in a group of male patients with hypogonadism, the diminished function of testicles for men or ovaries in women.
"The start of this trial is another meaningful step towards achieving Diurnal's vision of becoming one of the world's leading endocrinology speciality pharma companies," said Martin Whitaker, Diurnal's chief executive.
Diurnal shares were untraded on Monday, having last traded at 110.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
